Review Article

Importance of Postprandial Glucose Levels as a Target for Glycemic Control in Type 2 Diabetes

Authors: Joseph Tibaldi MD

Abstract

Abstract:Increasing evidence supports the importance of postprandial glucose (PPG) in glycemic control with regard to the development of complications in patients with diabetes. PPG plays a critical role in determining overall glycemic control, particularly in patients who are close to their glycemic goals. Data also indicate that postprandial hyperglycemia may have a greater effect on the development of cardiovascular complications compared with elevated fasting plasma glucose. Several antidiabetic agents that specifically target PPG are currently available, including glinides, glucagon-like peptide-1 mimetics, dipeptidyl peptidase-4 inhibitors, and rapid-acting insulin analogs. A more intensive approach to managing PPG may improve the care of patients with diabetes and, ultimately, the outcome of these patients.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

References1. American Diabetes Association. Standards of medical care in diabetes–2008. Diabetes Care 2008;31(suppl 1):S12–S54.American Diabetes AssociationStandards of medical care in diabetes–2008.Diabetes Care200831S12-S542. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007;13(suppl 1):1–68.AACE Diabetes Mellitus Clinical Practice Guidelines Task ForceAmerican Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus.Endocr Pract2007131-683. Saaddine JB, Cadwell B, Gregg EW, et al. Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002. Ann Intern Med 2006;144:465–474.SaaddineJB]]CadwellB]]GreggEW&etal;Improvements in diabetes processes of care and intermediate outcomes: United States, 1988–2002.Ann Intern Med2006144465-4744. Lebovitz HE, Austin MM, Blonde L, et al; ACE/AACE Diabetes Recommendations Implementation Writing Committee. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract 2006;12(suppl 1):6–12.LebovitzHE]]AustinMM]]BlondeL&etal;ACE/AACE Diabetes Recommendations Implementation Writing CommitteeACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations.Endocr Pract2006126-125. American Diabetes Association. Postprandial blood glucose. American Diabetes Association. Diabetes Care 2001;24:775–778.American Diabetes AssociationPostprandial blood glucose. American Diabetes Association.Diabetes Care200124775-7786. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881–885.MonnierL]]LapinskiH]]ColetteCContributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).Diabetes Care200326881-8857. Erlinger TP, Brancati FL. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diabetes Care 2001;24:1734–1738.ErlingerTP]]BrancatiFLPostchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes.Diabetes Care2001241734-17388. Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo study. Diabetes Care 1998;21:1236–1239.Barrett-ConnorE]]FerraraAIsolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men. The Rancho Bernardo study.Diabetes Care1998211236-12399. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study. Diabetes Care 1998;21:360–367.BalkauB]]ShipleyM]]JarrettRJ&etal;High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study.Diabetes Care199821360-36710. Donahue RP, Abbott RD, Reed DM, et al. Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program. Diabetes 1987;36:689–692.DonahueRP]]AbbottRD]]ReedDM&etal;Postchallenge glucose concentration and coronary heart disease in men of Japanese ancestry. Honolulu Heart Program.Diabetes198736689-69211. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996;39:1577–1583.HanefeldM]]FischerS]]JuliusU&etal;Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.Diabetologia1996391577-158312. DECODE Study Group, the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001;161:397–405.DECODE Study Groupthe European Diabetes Epidemiology GroupGlucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria.Arch Intern Med2001161397-40513. Monnier L, Colette C, Boniface H. Contribution of postprandial glucose to chronic hyperglycaemia: from the “glucose triad” to the trilogy of “sevens.” Diabetes Metab 2006;32(spec no. 2):2S11–2S16.MonnierL]]ColetteC]]BonifaceHContribution of postprandial glucose to chronic hyperglycaemia: from the “glucose triad” to the trilogy of “sevens.”Diabetes Metab200632spec no. 22S11-2S1614. International Diabetes Federation. Guideline for Management of Postmeal Glucose. Belgium, Lesaffre printer, 2007, pp 1–29.International Diabetes FederationGuideline for Management of Postmeal Glucose.BelgiumLesaffre printer20071-2915. Charpentier G, Dardari D, Riveline JP. How should postprandial glycemia be treated? Diabetes Metab 2006;32(spec no. 2):2S21–2S27.CharpentierG]]DardariD]]RivelineJPHow should postprandial glycemia be treated?Diabetes Metab200632spec no. 22S21-2S2716. Cryer PE. Glucose homeostasis and hypoglycemia, in Kronenberg HM, Melmed S, Polonsky KS, et al (eds): Williams Textbook of Endocrinology. Philadelphia, Saunders Elsevier, 2008, pp 1503–1533.CryerPEGlucose homeostasis and hypoglycemiaKronenberg HM, Melmed S, Polonsky KSWilliams Textbook of Endocrinology.PhiladelphiaSaunders Elsevier20081503-153317. Mitrakou A, Kelley D, Mokan M, et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992;326:22–29.MitrakouA]]KelleyD]]MokanM&etal;Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.N Engl J Med199232622-2918. Kelley D, Mokan M, Veneman T. Impaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus. Metabolism 1994;43:1549–1557.KelleyD]]MokanM]]VenemanTImpaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus.Metabolism1994431549-155719. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005;54:1615–1625.BrownleeMThe pathobiology of diabetic complications: a unifying mechanism.Diabetes2005541615-162520. O’Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007;100:899–904.O’KeefeJH]]BellDSPostprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor.Am J Cardiol2007100899-90421. Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187–218.WajchenbergBLBeta-cell failure in diabetes and preservation by clinical treatment.Endocr Rev200728187-21822. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006;295:1681–1687.MonnierL]]MasE]]GinetC&etal;Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes.JAMA20062951681-168723. Ceriello A, Lush CW, Darsow T, et al. Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes. Diabetes Metab Res Rev 2008;24:103–108.CerielloA]]LushCW]]DarsowT&etal;Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.Diabetes Metab Res Rev200824103-10824. Ceriello A, Hanefeld M, Leiter L, et al. Postprandial glucose regulation and diabetic complications. Arch Intern Med 2004;164:2090–2095.CerielloA]]HanefeldM]]LeiterL&etal;Postprandial glucose regulation and diabetic complications.Arch Intern Med20041642090-209525. de Vegt F, Dekker JM, Jager A, et al. Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study. JAMA 2001;285:2109–2113.de VegtF]]DekkerJM]]JagerA&etal;Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study.JAMA20012852109-211326. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. The DECODE-study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: collaborative analysis of Diagnostic Criteria in Europe. Diabetologia 1999;42:647–654.&NA;Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. The DECODE-study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: collaborative analysis of Diagnostic Criteria in Europe.Diabetologia199942647-65427. Jackson CA, Yudkin JS, Forrest RD. A comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community. The Islington Diabetes Survey. Diabetes Res Clin Pract 1992;17:111–123.JacksonCA]]YudkinJS]]ForrestRDA comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community. The Islington Diabetes Survey.Diabetes Res Clin Pract199217111-12328. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004;141:421–431.SelvinE]]MarinopoulosS]]BerkenblitG&etal;Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.Ann Intern Med2004141421-43129. Laakso M. Hyperglycemia as a risk factor for cardiovascular disease in type 2 diabetes. Prim Care 1999;26:829–839.LaaksoMHyperglycemia as a risk factor for cardiovascular disease in type 2 diabetes.Prim Care199926829-83930. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–412.StrattonIM]]AdlerAI]]NeilHA&etal;Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.BMJ2000321405-41231. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854–865.&NA;Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.Lancet1998352854-86532. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837–853.&NA;Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.Lancet1998352837-85333. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977–986.&NA;The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group.N Engl J Med1993329977-98634. Balkau B, Eschwege E. Epidemiological data on postprandial glycaemia. Diabetes Metab 2006;32(spec no. 2):2S5–2S9.BalkauB]]EschwegeEEpidemiological data on postprandial glycaemia.Diabetes Metab200632spec no. 22S5-2S935. Gabir MM, Hanson RL, Dabelea D, et al. Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 2000;23:1113–1118.GabirMM]]HansonRL]]DabeleaD&etal;Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes.Diabetes Care2000231113-111836. Schulze MB, Liu S, Rimm EB, et al. Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am J Clin Nutr 2004;80:348–356.SchulzeMB]]LiuS]]RimmEB&etal;Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women.Am J Clin Nutr200480348-35637. Brand-Miller JC. Postprandial glycemia, glycemic index, and the prevention of type 2 diabetes. Am J Clin Nutr 2004;80:243–244.Brand-MillerJCPostprandial glycemia, glycemic index, and the prevention of type 2 diabetes.Am J Clin Nutr200480243-24438. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study. Am J Med 1997;103:483–490.HoffmannJ]]SpenglerMEfficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II Study.Am J Med1997103483-49039. Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000;23:1660–1665.HortonES]]ClinkingbeardC]]GatlinM&etal;Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.Diabetes Care2000231660-166540. Gastaldelli A, Ferrannini E, Miyazaki Y, et al. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 2007;292:E871–E883.GastaldelliA]]FerranniniE]]MiyazakiY&etal;Thiazolidinediones improve beta-cell function in type 2 diabetic patients.Am J Physiol Endocrinol Metab2007292E871-E88341. Bell DS, O’Keefe JH, Jellinger P. Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events? Endocr Pract 2008;14:112–124.BellDS]]O’KeefeJH]]JellingerPPostprandial dysmetabolism: the missing link between diabetes and cardiovascular events?Endocr Pract200814112-12442. Kahn SE, Montgomery B, Howell W, et al. Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001;86:5824–5829.KahnSE]]MontgomeryB]]HowellW&etal;Importance of early phase insulin secretion to intravenous glucose tolerance in subjects with type 2 diabetes mellitus.J Clin Endocrinol Metab2001865824-582943. Esposito K, Giugliano D, Nappo F, et al; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004;110:214–219.EspositoK]]GiuglianoD]]NappoF&etal;Campanian Postprandial Hyperglycemia Study GroupRegression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus.Circulation2004110214-21944. Kalbag JB, Walter YH, Nedelman JR, et al. Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo. Diabetes Care 2001;24:73–77.KalbagJB]]WalterYH]]NedelmanJR&etal;Mealtime glucose regulation with nateglinide in healthy volunteers: comparison with repaglinide and placebo.Diabetes Care20012473-7745. Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004;27:1265–1270.RosenstockJ]]HassmanDR]]MadderRD&etal;Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.Diabetes Care2004271265-127046. Raskin P, McGill J, Saad MF, et al; Repaglinide/Rosiglitazone Study Group. Combination therapy for type 2 diabetes: repaglinide plus rosiglitazone. Diabet Med 2004;21:329–335.RaskinP]]McGillJ]]SaadMF&etal;Repaglinide/Rosiglitazone Study GroupCombination therapy for type 2 diabetes: repaglinide plus rosiglitazone.Diabet Med200421329-33547. Raskin P, Klaff L, McGill J, et al; Repaglinide vs. Nateglinide Metformin Combination Study Group. Efficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003;26:2063–2068.RaskinP]]KlaffL]]McGillJ&etal;Repaglinide vs. Nateglinide Metformin Combination Study GroupEfficacy and safety of combination therapy: repaglinide plus metformin versus nateglinide plus metformin.Diabetes Care2003262063-206848. Moses R, Slobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 1999;22:119–124.MosesR]]SlobodniukR]]BoyagesS&etal;Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.Diabetes Care199922119-12449. Damsbo P, Clauson P, Marbury TC, et al. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 1999;22:789–794.DamsboP]]ClausonP]]MarburyTC&etal;A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients.Diabetes Care199922789-79450. Hatorp V, Huang WC, Strange P. Pharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes. J Clin Endocrinol Metab 1999;84:1475–1478.HatorpV]]HuangWC]]StrangePPharmacokinetic profiles of repaglinide in elderly subjects with type 2 diabetes.J Clin Endocrinol Metab1999841475-147851. Shimabukuro M, Higa N, Chinen I, et al. Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 2006;91:837–842.ShimabukuroM]]HigaN]]ChinenI&etal;Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study.J Clin Endocrinol Metab200691837-84252. Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006;29:435–449.RiddleMC]]DruckerDJEmerging therapies mimicking the effects of amylin and glucagon-like peptide 1.Diabetes Care200629435-44953. Rendell MS, Jovanovic L. Targeting postprandial hyperglycemia. Metabolism 2006;55:1263–1281.RendellMS]]JovanovicLTargeting postprandial hyperglycemia.Metabolism2006551263-128154. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006;368:1696–1705.DruckerDJ]]NauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.Lancet20063681696-170555. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929–2940.DruckerDJEnhancing incretin action for the treatment of type 2 diabetes.Diabetes Care2003262929-294056. Deacon CF. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004;53:2181–2189.DeaconCFTherapeutic strategies based on glucagon-like peptide 1.Diabetes2004532181-218957. Vilsboll T, Zdravkovic M, Le-Thi T, et al. Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608–1610.VilsbollT]]ZdravkovicM]]Le-ThiT&etal;Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.Diabetes Care2007301608-161058. Madsbad S, Krarup T, Deacon CF, et al. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008;11:491–499.MadsbadS]]KrarupT]]DeaconCF&etal;Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.Curr Opin Clin Nutr Metab Care200811491-49959. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194–206.AmoriRE]]LauJ]]PittasAGEfficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.JAMA2007298194-20660. Degn KB, Juhl CB, Sturis J, et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004;53:1187–1194.DegnKB]]JuhlCB]]SturisJ&etal;One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes.Diabetes2004531187-119461. Ahren B, Schmitz O. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes. Horm Metab Res 2004;36:867–876.AhrenB]]SchmitzOGLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.Horm Metab Res200436867-87662. Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. Diabetes Care 2007;30:217–223.RosenstockJ]]BaronMA]]DejagerS&etal;Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.Diabetes Care200730217-22363. Vilsboll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 2007;16:231–237.VilsbollTLiraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus.Expert Opin Investig Drugs200716231-23764. Mari A, Sallas WM, He YL, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005;90:4888–4894.MariA]]SallasWM]]HeYL&etal;Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes.J Clin Endocrinol Metab2005904888-489465. Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174–183.HirschIBInsulin analogues.N Engl J Med2005352174-18366. Ceriello A, Cavarape A, Martinelli L, et al. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004;21:171–175.CerielloA]]CavarapeA]]MartinelliL&etal;The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart.Diabet Med200421171-17567. Vazquez-Carrera M, Silvestre JS. Insulin analogues in the management of diabetes. Methods Find Exp Clin Pharmacol 2004;26:445–461.Vazquez-CarreraM]]SilvestreJSInsulin analogues in the management of diabetes.Methods Find Exp Clin Pharmacol200426445-46168. Dailey G, Rosenstock J, Moses RG, et al. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004;27:2363–2368.DaileyG]]RosenstockJ]]MosesRG&etal;Insulin glulisine provides improved glycemic control in patients with type 2 diabetes.Diabetes Care2004272363-236869. Heller SR, Colagiuri S, Vaaler S, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. Diabet Med 2004;21:769–775.HellerSR]]ColagiuriS]]VaalerS&etal;Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes.Diabet Med200421769-77570. Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005;165:1337–1344.PlankJ]]SiebenhoferA]]BergholdA&etal;Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus.Arch Intern Med20051651337-134471. Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther 2005;27:1113–1125.RollaAR]]RakelREPractical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues.Clin Ther2005271113-112572. Iwamoto Y. A randomised, multicentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes. Diabetologia 2003;46(suppl 2):A270.IwamotoYA randomised, multicentre trial of biphasic insulin aspart versus biphasic human insulin in type 2 diabetes.Diabetologia200346A27073. Malone JK, Yang H, Woodworth JR, et al. Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes. Diabetes Metab 2000;26:481–487.MaloneJK]]YangH]]WoodworthJR&etal;Humalog Mix25 offers better mealtime glycemic control in patients with type 1 or type 2 diabetes.Diabetes Metab200026481-48774. Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002;25:724–730.WhitehouseF]]KrugerDF]]FinemanM&etal;A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.Diabetes Care200225724-73075. Hollander P, Ratner R, Fineman M, et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets. Diabetes Obes Metab 2003;5:408–414.HollanderP]]RatnerR]]FinemanM&etal;Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets.Diabetes Obes Metab20035408-41476. Ratner RE, Want LL, Fineman MS, et al. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol Ther 2002;4:51–61.RatnerRE]]WantLL]]FinemanMS&etal;Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.Diabetes Technol Ther2002451-6177. Maggs DG, Fineman M, Kornstein J, et al. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study. Diabetes Metab Res Rev 2004;20:55–60.MaggsDG]]FinemanM]]KornsteinJ&etal;Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.Diabetes Metab Res Rev20042055-6078. Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359:2072–2077.ChiassonJL]]JosseRG]]GomisR&etal;STOP-NIDDM Trial Research GroupAcarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.Lancet20023592072-207779. Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003;290:486–494.ChiassonJL]]JosseRG]]GomisR&etal;STOP-NIDDM Trial Research GroupAcarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.JAMA2003290486-49480. Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004;25:10–16.HanefeldM]]CagatayM]]PetrowitschT&etal;Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.Eur Heart J20042510-1681. Hanefeld M, Chiasson JL, Koehler C, et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004;35:1073–1078.HanefeldM]]ChiassonJL]]KoehlerC&etal;Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance.Stroke2004351073-107882. Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998;83:1515–1522.JohnstonPS]]LebovitzHE]]ConiffRF&etal;Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients.J Clin Endocrinol Metab1998831515-152283. Yamasaki Y, Katakami N, Hayaishi-Okano R, et al. Alpha-glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res Clin Pract 2005;67:204–210.YamasakiY]]KatakamiN]]Hayaishi-OkanoR&etal;Alpha-glucosidase inhibitor reduces the progression of carotid intima-media thickness.Diabetes Res Clin Pract200567204-21084. Mita T, Watada H, Shimizu T, et al. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol 2007;27:2456–2462.MitaT]]WatadaH]]ShimizuT&etal;Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control.Arterioscler Thromb Vasc Biol2007272456-2462